Tectonic Therapeutic
Sarah Nordeen has been working in the field of science since 2012. Sarah began as an Undergraduate Researcher at the University of Wisconsin-Madison, Yoon Group, Department of Chemistry in 2012. In 2013, they took on a position as an Undergraduate Researcher at the University of Cambridge. From 2014 to 2020, they were a Graduate Student at the Massachusetts Institute of Technology. Most recently, they have been working as a Scientist II and Scientist I at Tectonic Therapeutic, Inc. in the role of Antibody Engineering.
Sarah Nordeen attended the University of Wisconsin-Madison from 2010 to 2014, where they earned a Bachelor of Science (BS) with Distinction in Biochemistry. Sarah then went on to pursue a Doctor of Philosophy - PhD in Biophysical Chemistry and Molecular Structure at the Massachusetts Institute of Technology, graduating in 2020.
Tectonic Therapeutic
5 followers
Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs).